Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SITAGLIPTIN

All products: general benefit

Other products in the same Health Canada class (A10B, A10BH) — coverage varies; not interchangeable

  • Linagliptin (Trajenta): general benefit
  • Saxagliptin (Onglyza): general benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin (Jardiance): general benefit

12 more in the class list below

Januvia · DIN 02303922 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Januvia · DIN 02303922 Manufacturer: Merck Frosst Canada Ltd.; listing date 2010-06-14 Health Canada: Marketed since 2008-01-02 · brand JANUVIA · ATC A10BH01 SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100 MG · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.8197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78924 · Verify on the e-Formulary ↗ (DIN 02303922)

Source record
DIN 02303922: Januvia Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002034; group id 756; item number 1856; lccId None; manufacturer id MFC Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $3.4098; ministry $0.8197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02303922 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78924 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximal doses of metformin (2000mg/day)who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; or . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.
Interchangeable products
Ach-Sitagliptin · DIN 02512491 · $0.8197 Apo-Sitagliptin · DIN 02428296 · $0.8197 Apo-Sitagliptin Malate · DIN 02508672 · $0.8197 Auro-Sitagliptin · DIN 02529882 · $0.8197 Jamp Sitagliptin · DIN 02534150 · $0.8197 M-Sitagliptin · DIN 02535009 · $0.8197 Mint-Sitagliptin · DIN 02553937 · $0.8197 NAT-Sitagliptin · DIN 02543400 · $0.8197 PMS-Sitagliptin · DIN 02503867 · $0.8197 PRZ-Sitagliptin · DIN 02545853 · $0.8197 Sandoz Sitagliptin · DIN 02504065 · $0.8197 Sitagliptin · DIN 02529068 · $0.8197 Sitagliptin · DIN 02548577 · $0.8197 Taro-Sitagliptin Fumarate · DIN 02531666 · $0.8197 Teva-Sitagliptin Malate · DIN 02522721 · $0.8197
Shortage status: resolved shortage (ended 2023-02-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02303922
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:02 and 6 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS • Monotherapy: JANUVIA® (sitagliptin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance. • Add-on combination: JANUVIA® is indicated in adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: . metformin, . metformin and a sulfonylurea, . pioglitazone (alone or with metformin), . premixed or long/intermediate acting insulin (alone or with metformin) when the existing therapy, along with diet and exercise, does not provide adequate glycemic control (see 14 CLINICAL TRIALS). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of JANUVIA®in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics • Geriatrics (≥65 years of age): Based on the data submitte… https://pdf.hres.ca/dpd_pm/00074500.PDF PM date: FEB 07, 2024 Source product: JANUVIA; DIN 02303922; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.